Updates in the Incidence, Pathogenesis, and Management of Cancer and Venous Thromboembolism

Girardi, Laura; Wang, Tzu‐Fei; Ageno, Walter; Carrier, Marc

doi:10.1161/atvbaha.123.318779

Cited by 15 publications

(13 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 56 patients with stage IV melanoma displayed sCLEC-2 levels comparable with healthy donors but significantly higher compared to stage I to III melanoma. Melanoma patients have a considerably higher risk of suffering from VTE than patients with CRC or BC [29][30][31]. In stage IV melanoma a prevalence of VTE of 25 % was observed [29].…”

Section: Discussionmentioning

confidence: 99%

C-Type Lectin-like Receptor 2 Expression Is Decreased upon Platelet Activation and Is Lower in Most Tumor Entities Compared to Healthy Controls

Etemad,

Christodoulou,

Uhlig

et al. 2023

Preprint

View full text Add to dashboard Cite

The C-type lectin-like receptor 2 (CLEC-2) is expressed on platelets and mediates binding to podoplanin (PDPN) on various cell types. The binding to circulating tumor cells (CTCs) leads to platelet activation and promote metastatic spread. The increased level of soluble CLEC-2 (sCLEC-2), presumably, released from activated platelets was shown in patients with thromboinflammatory and malignant disease. However, the functional role of sCLEC-2 and the mechanism of sCLEC-2 release is not known. In this study, we focused on the effect of platelet activation on CLEC-2 expression and the sCLEC-2 plasma level in cancer patients. First, citrated blood from healthy volunteer donors (n=20) was used to measure the effect of platelet stimulation by classical agonists and PDPN on aggregation, CLEC-2 expression on platelets by flow cytometry, sCLEC-2 release to the plasma by ELISA and total CLEC-2 expression by Western blot analysis. Second, sCLEC-2 was determined in plasma samples from healthy donors (285) and patients with colorectal carcinoma (CRC; 194), melanoma (160), breast cancer (BC; 99) or glioblastoma (49). PDPN caused a significant increase of the aggregation response induced by classical agonists. ADP or PDPN stimulation of platelets caused a significant decrease of CLEC-2 on platelets and sCLEC-2 in the plasma, whereas, total CLEC-2 in platelet lysates remained the same. Thus, the increased plasma level of sCLEC-2 is not a suitable biomarker of platelet activation. In patients with CRC (median 0.9 ng/mL), melanoma (0.9 ng/mL) or BC (0.7 ng/mL) we found significantly lower sCLEC-2 levels (p&lt;0.0001), whereas, glioblastoma patients displayed higher levels (2.6 ng/mL; p=0.0233) compared to healthy controls (2.1 ng/mL). The low sCLEC-2 plasma level observed in most of the tumor entities of our study, presumably, results from the internalization of sCLEC-2 by activated platelets or binding of sCLEC-2 to CTC.

show abstract

Section: Discussionmentioning

confidence: 99%

C-Type Lectin-like Receptor 2 Expression Is Decreased upon Platelet Activation and Is Lower in Most Tumor Entities Compared to Healthy Controls

Etemad,

Christodoulou,

Uhlig

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…[1] Cancer-associated VTE has become a major issue in contemporary patients with cancer. [2,3] Recent randomized clinical trials (RCT) have demonstrated that direct oral anticoagulants (DOAC) are potential alternatives to low-molecular-weight heparin (LMWH), the standard anticoagulation therapy for cancer-associated VTE. [4][5][6][7] In addition, several meta-analyses have consistently suggested the utility of DOACs for cancer-associated VTE.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

“…Proximal deep vein thrombosis (DVT) in lower extremities was defined as venous thrombosis which was located in popliteal, femoral, or iliac veins. Anemia was defined as hemoglobin level <13 g/dL for men and <12 g/dL for women according to the standard World Health Organization classification of anemia 3 . Thrombocytopenia was defined as platelet count <100×10 9 /L 4 .…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Edoxaban, Rivaroxaban, or Apixaban for Cancer-Associated Venous Thromboembolism in the Real World: Insights from the COMMAND VTE Registry-2

Sueta,

Yamashita,

Morimoto

et al. 2024

Thromb Haemost

View full text Add to dashboard Cite

Background: Real-world data on clinical characteristics and outcomes related to the use of different direct oral anticoagulants (DOACs) for cancer-associated venous thromboembolism (VTE) is lacking. Methods: The COMMAND VTE Registry-2 is a multicenter registry enrolling 5,197 consecutive patients with acute symptomatic VTE from 31 centers in Japan from January 2015–August 2020. Our study population comprised 1,197 patients with active cancer who were divided into the edoxaban (N=643, 54%), rivaroxaban (N=297, 25%), and apixaban (N=257, 22%) groups. Results: The cumulative 5-year incidence of recurrent VTE (9.3%, 10.2%, and 8.5%, respectively, P=0.82) and all-cause death (67.5%, 66.8%, and 63.8%, respectively, P=0.22) did not differ among the groups. Despite adjusting for confounders, the risks of recurrent VTE and all-cause death did not differ significantly among the groups. The cumulative 5-year incidence of major and clinically relevant bleeding was significantly lower in the rivaroxaban group than those in the other groups (22.6%, 14.0%, and 22.8%, P=0.04; and 37.6%, 26.8%, and 38.3%, P=0.01, respectively). After adjusting for confounders, in the rivaroxaban group, the risk for major bleeding was numerically lower (HR: 0.65, 95% CI: 0.40–1.01) and that of clinically relevant all bleeding was significantly lower (HR: 0.67, 95% CI: 0.48–0.92) than those in the edoxaban group. Conclusions: The risks of recurrent VTE and all-cause death did not differ significantly among the different DOACs ; however, the risk of bleeding events could differ, with a potentially lower risk of bleeding with rivaroxaban.

show abstract

“…VTE is a serious medical concern affecting an increasing number of individuals worldwide, becoming a significant economic burden globally. The incidence of VTE in the general population is reported to be 1‰-2‰ [2], with rates in the European population ranging from 1.04‰ to 1.83‰. Although the incidence in the Asian population is slightly lower, recent years have witnessed an upward trend [3], with VTE cases in Hong Kong increasing from 28.1 cases per 100,000 to 48.3 cases per 100,000 between 2004 and 2016.…”

Section: Introductionmentioning

confidence: 99%

Seasonal Variations of Venous Thromboembolism Incidence: A Systemic Review from Global Trends to Chinese Context

Li,

Uzokov,

Sun

et al. 2024

HSF

View full text Add to dashboard Cite

Background: Venous thromboembolism (VTE) is a significant global health concern with seasonal variations in its incidence. Understanding these patterns is crucial for effective prevention and management strategies. Methods: Utilizing the PRISMA guidelines, our literature selection process involved systematic screening of both English and Chinese articles. From 21 included studies, involving 98,877 VTE patients, we conducted a meta-analysis examining global and China-specific VTE incidence patterns. Subgroup analyses were performed for pulmonary embolism (PE) and deep vein thrombosis (DVT). Results: In the global context, VTE incidence varied across seasons, with significantly lower rates observed in summer compared to winter (relative risk (RR) = 0.90, 95% confidence interval (CI): 0.84–0.98, p = 0.010). PE incidence was lower in summer compared to autumn/winter (RR = 0.93, 95% CI: 0.89–0.97 summer/autumn; RR = 0.90, 95% CI: 0.84–0.98 summer/winter). Conversely, DVT incidence was higher in winter compared to summer (RR = 0.80, 95% CI: 0.66–0.86, p = 0.02). In China, VTE incidence was lower in spring compared to winter (RR = 0.83, 95% CI: 0.72–0.96; p = 0.010), with no significant differences between winter and summer or autumn. Conclusion: Our study underscores the importance of considering seasonal and regional factors in understanding VTE incidence. The findings contribute valuable insights for healthcare professionals and policymakers, emphasizing the need for tailored strategies in different geographical areas to address and prevent VTE effectively.

show abstract

Updates in the Incidence, Pathogenesis, and Management of Cancer and Venous Thromboembolism

Cited by 15 publications

References 79 publications

C-Type Lectin-like Receptor 2 Expression Is Decreased upon Platelet Activation and Is Lower in Most Tumor Entities Compared to Healthy Controls

C-Type Lectin-like Receptor 2 Expression Is Decreased upon Platelet Activation and Is Lower in Most Tumor Entities Compared to Healthy Controls

Edoxaban, Rivaroxaban, or Apixaban for Cancer-Associated Venous Thromboembolism in the Real World: Insights from the COMMAND VTE Registry-2

Seasonal Variations of Venous Thromboembolism Incidence: A Systemic Review from Global Trends to Chinese Context

Contact Info

Product

Resources

About